Caxton Corp.
In its 13F for Q3 2024 (holdings as of September 30, 2024, filed November 14, 2024), Caxton Corp. reported 12 stock positions worth $24.2 million. Its top holding was Xeris Biopharma (XERS) at 60.3% of the portfolio, followed by Rezolute (RZLT, 26.5%) and SS SPDR S&P 500 ETF Trust-US (SPY, 6.8%). Compared with Q2 2024, it opened 1 new position, sold out of 1, added to 3 and reduced 1. The biggest buy was SS SPDR S&P 500 ETF Trust-US (SPY, shares +53%) and the biggest sale an exit from Molecular Templates (MTEMQ).
- Most Recent 13F
- Q2 2026
- Location
- Princeton, NJ
- CIK
- 0001388551
- Portfolio Value
- $24.2M (Q3 2024)
- SEC Filing
- 0000919574-24-006599 ↗ filed Nov 14, 2024
Holdings Value
Holdings 12 stocks · $24.2M
| XERS Xeris Biopharma Holdings Inc. | 60.31% | 5,113,348 | $14.6M | No change |
| RZLT Rezolute Inc. | 26.47% | 1,318,967 | $6.4M | No change |
| SPY SS SPDR S&P 500 ETF Trust-US | 6.81% | 2,867 | $1.6M | Add +53.4% |
| BRK.B Berkshire Hathaway Inc. Class B | 2.19% | 1,151 | $530K | Add +12.3% |
| BCAX Bicara Therapeutics Inc. | 1.15% | 10,941 | $279K | New |
| MIND MEDICINE MINDMED INC | 0.80% | 34,073 | $194K | Add +12.1% |
| LXEO Lexeo Therapeutics Inc. | 0.67% | 17,851 | $161K | No change |
| ABVX Abivax SA-ADR | 0.54% | 11,365 | $131K | Reduce -18.2% |
| KYTX Kyverna Therapeutics Inc. | 0.47% | 22,981 | $112K | No change |
| CMPX Compass Therapeutics Inc. | 0.33% | 43,465 | $80K | No change |
| CNTX Context Therapeutics Inc. | 0.15% | 18,403 | $36K | No change |
| ACET Adicet Bio Inc. | 0.10% | 17,488 | $25K | No change |
Portfolio Sells Q2 2024 → Q3 2024
Portfolio Buys Q2 2024 → Q3 2024
| SPY SS SPDR S&P 500 ETF Trust-US | Add +53.4% | 6.81% | +1.65 |
| BCAX Bicara Therapeutics Inc. | New | 1.15% | +1.15 |
| BRK.B Berkshire Hathaway Inc. Class B | Add +12.3% | 2.19% | +0.08 |
| MIND MEDICINE MINDMED INC | Add +12.1% | 0.80% | −0.31 |
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 10 | $1.9M | SPCX, BRK.B, GOOGL, VOO, BX |
| Q1 2026 | 7 | $4.0M | GLD, BRK.B, KYTX, LXEO, XFOR |
| Q4 2025 | 11 | $4.3M | GLD, BRK.B, SYRE, MIND MEDICINE MINDMED INC, KYTX |
| Q3 2025 | 12 | $22.9M | RZLT, GLD, BRK.B, MIND MEDICINE MINDMED INC, ELVN |
| Q2 2025 | 11 | $9.9M | RZLT, GLD, BRK.B, ELVN, MIND MEDICINE MINDMED INC |
| Q1 2025 | 12 | $5.1M | RZLT, GLD, BRK.B, MIND MEDICINE MINDMED INC, BCAX |
| Q4 2024 | 15 | $16.6M | XERS, RZLT, SPY, BRK.B, GLD |
| Q3 2024 | 12 | $24.2M | XERS, RZLT, SPY, BRK.B, BCAX |
| Q2 2024 | 12 | $19.7M | XERS, RZLT, SPY, BRK.B, LXEO |
| Q1 2024 | 11 | $17.6M | XERS, RZLT, SPY, BRK.B, KYTX |